Innogenetics Reports Results for the First Half of 2003 in Line with Expectations
August 19, 2003 03:39 ET
|
Innogenetics
GENT, Belgium, Aug. 19, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced its unaudited results for the first half ending June 30, 2003.
First half 2003 highlights (versus first...
Innogenetics Reports Results for the First Quarter of 2003 in Line with Expectations
May 15, 2003 03:53 ET
|
Innogenetics
GENT, Belgium, May 15, 2003 (PRIMEZONE) -- Innogenetics today announced its results for the first quarter ending March 31, 2003.
First quarter 2003 highlights (versus first quarter 2002)
-...
Innogenetics Announces Positive Results in Pivotal Preclinical Study in Sepsis
May 06, 2003 02:45 ET
|
Innogenetics
GENT, Belgium, May 6, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today reported the results of its pivotal preclinical evaluation of a proprietary anti-inflammatory monoclonal antibody, INNO...
Innogenetics' Outlook for 2003 -- Enhanced Financial Prospects and Promising New Therapeutic Developments
January 15, 2003 02:21 ET
|
Innogenetics
GENT, Belgium, Jan. 15, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced the preliminary indications of its year 2002 financial results, offered an initial outlook for 2003 and...
Innogenetics Reports Profitable Diagnostics Activities and Increased R&D Investments for the First Nine Months of 2002
November 15, 2002 04:09 ET
|
Innogenetics
GENT, Belgium, Nov. 15, 2002 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced its results for the first nine months ending September 30, 2002.
Highlights
-- Diagnostics Division...
Innogenetics Announces Positive Liver Histology Results of Its Hepatitis C Therapeutic Vaccine
October 17, 2002 03:51 ET
|
Innogenetics
GENT, Belgium, Oct. 17, 2002 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced the first liver histology results of its E1-based therapeutic candidate vaccine in 24 patients chronically...